Skip to content

Efficacy and safety evaluation of domestic ticagrelor (taiyi)

A randomized, parallel controlled trial for evaluation of the efficacy, safety and pharmacokinetic characteristics of antiplatelet aggregation in patients with coronary atherosclerotic heart disease undergoing percutaneous coronary intervention using ticagrelor

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023826
Enrollment
Unknown
Registered
2019-06-13
Start date
2019-06-30
Completion date
Unknown
Last updated
2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute coronary syndrome

Interventions

Brilinta group:Patiens will be given Brilinta
Taiyi group:Patients will be given TaiYi.

Sponsors

Tianjin Union Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years, regardless of gender; 2. Weight 50 kg or more; 3. Meet the diagnose standard of acute coronary syndrome (ACS); 4. Patients planning to undergo PCI; 5. To be able and willing to sign informed consent and comply with the study protocol.

Exclusion criteria

Exclusion criteria: 1. Bleeding symptoms (e.g. Hematemesis,Black stool, severe or recurrent nosebleed, hemoptysis, apparent hematuria, gastrointestinal bleeding or intracranial bleeding, or suspected vascular malformation (such as aneurysm),If he/she has a history of abnormal bleeding (e.g. abnormal bleeding at tooth extraction), or if he/she or his/her immediate family member has coagulation or bleeding disease (e.g. hemophilia); 2. Acute patients with st-segment elevation myocardial infarction after thrombolytic therapy; 3. Suspected patients with aortic dissection; 4. The stenosis degree of the left main artery is suspected to be more than 50%; 5. The total number of stent implantation is expected to be > 3 ; 6. Patients with negative coronary artery CT (whether or not to receive coronary artery CT was determined by the researcher); 7. Serious illness; Patients, life expectancy 1.3 times the upper limit of normal value or international standard ratio (INR) >2.0; 20. Platelet count (PLT) 600×10^9/L; 21. Hemoglobin level <10g/dL; 22. Cannot tolerate 28-day couplets; Patients treated with antiplatelet agents; 23. Positive pregnancy test results of women of reproductive age during screening; 24. Women in the study who were willing to conceive, A lactating woman; 25. The researcher believes that the patient has other conditions that are not suitable for participating in this study.

Design outcomes

Primary

MeasureTime frame
Platelet aggregation rate;

Countries

China

Contacts

Public ContactZhuhua Yao

Tianjin Union Medical Center

tjyzhpci@163.com+86 13902199877

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026